A Phase II Clinical Trial of Carbon-ion Radiotherapy Combined with Gemcitabine for Locally Advanced Pancreatic Cancer - Carbon-ion Radiotherapy wih Gemcitabine for Pancreatic Cancer (iROCK1605PA)

Kanagawa Cancer Center, Kanagawa Prefectural Hospital Organization0 个研究点目标入组 45 人开始时间: 2017年4月12日最近更新: 2024年4月1日

适应症

试验速览

暂无简介。

•1) Finding of direct invasion in gastrointestinal duct as followings: (a) Obvious finding of invasion in the stomach or duodenum in gastrointestinal endoscopy (b) Invasive lesion protruding inside of gastrointestine in imaging studies such as computed tomography (CT) 2) Ascites found by the abdominal-pelvic CT 3) Gastric or duodenal ulcer except for ulcer scar 4) Patient with metallic stent for occlusive jaundice 5) Open wound or active and intractable infection in the target lesion of irradiation 6) Severe complications such as severe stroke, diabetes, heart disease, angina, myocardial infarction developed within 3 months, severe liver dysfunction and psychologic disease 7) Active double cancer including concurrent or metachronous tumor within two years, except for lesion equivalent to carcinoma in situ or intramucosal cancer which is completely treated by local therapeutic procedure. 8) Previous history of radiotherapy for targeted lesion 9) Conditions that attending physicians consider unsuitable for this clinical study due to medical or psychological issues

发起方

Kanagawa Cancer Center, Kanagawa Prefectural Hospital Organization